patent application filing drift
What it checks
Companies whose 12-month patent-application count hits the top decile of their own history are accelerating R&D 18-24 months ahead of the commercialization curve. Long on entry, hold 1-2 years.
Mechanism
Patent applications precede grants by 18-24 months, giving an earlier window into the innovation pipeline than the existing patent_innovation_premium family (which uses grants). A 12-month rolling application count in the top decile of a ticker's own 5y history signals a discrete R&D acceleration that the market under-prices because of the lag to commercialization. Distinct from patent_class_drift (CPC pivots) and patent_litigation_loss_drift (defensive IP).
Signal rule
Long T+1 when 12-month rolling patent-application count for the ticker crosses the top decile (or top 5%) of the ticker's own 5y history. Hold 252 / 504 trading days (1y / 2y).
Data dependencies
daily_pricesAdjusted-close OHLCV for every US-listed ticker; primary price feed.
uspto_patent_applicationsWorker data table — see services/worker schema.
Expected edge
- Paper alpha
- 18-24mo innovation lead (vs KPSS grant-based panels)
- Paper window
- T+1 to T+504d
18-24 month innovation lead time vs grant-based families (which see the same firm 18-24 months later).
Example tickers where this is likely to fire
Illustrative only — the signal fires based on the live data, not a fixed list.
Related families
patent innovation premiumNetwork-EffectsPatent values inferred from 3-day stock reaction to USPTO grant. Firms with high value of recently granted patents (relative to market cap) outperform by ~3-5%/yr — real options on growth the market under-prices until citations validate.
patent class driftInnovationCohen-Diether-Malloy 2013 RFS document that firms reallocating R&D / patent filings toward different technology classes earn 7-9% ann. abnormal returns over 1-2y. The market under-weights narrative pivots — patent-class shifts signal a real business reorientation that sell-side estimates don't reflect in real time. We proxy class-pivot via the rolling z-score of KPSS monthly innovation-value (highly correlated with the class-entropy delta in the paper's appendix).
rd capitalized valueAccountingStandard book-to-market based value factors mis-classify R&D-heavy firms as "growth" because R&D is expensed (not capitalized) under GAAP. Peters-Taylor 2017 + Eisfeldt-Kim-Papanikolaou 2020 show that adding capitalized R&D back to book equity restores the value premium for tech/biotech and reverses the apparent "value-is-dead" finding of the 2010s. We compute an R&D-intensity metric per ticker and overweight it when it's accompanied by a price drawdown — the intangibles-implied value play.
Explore patent application filing drift on alphactor.ai
See which tickers this family is currently firing on, with live signals and rankings.